DRUG DELIVERY IMPLANTS FOR INHIBITION OF OPTICAL DEFECTS
    8.
    发明申请
    DRUG DELIVERY IMPLANTS FOR INHIBITION OF OPTICAL DEFECTS 审中-公开
    用于抑制光学缺陷的药物递送植入物

    公开(公告)号:US20100114309A1

    公开(公告)日:2010-05-06

    申请号:US12521543

    申请日:2007-12-21

    IPC分类号: A61F2/16

    摘要: An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.

    摘要翻译: 用于眼睛的植入物包括可植入结构和治疗剂。 治疗剂可以从结构递送到眼睛中,以便治疗影响和/或稳定眼睛的折射性质。 在许多实施例中,眼睛的屈光性可以包括近视,远视或散光中的至少一种。 治疗剂可以包含治疗影响或稳定眼睛的折射性质的组合物。 治疗剂可以包括散瞳剂或瘫痪药物中的至少一种。 例如,治疗剂可以包括睫状肌麻痹症,其包括阿托品,环戊二酸酯,琥珀酰胆碱,同质素,东莨菪碱或托品酰胺中的至少一种。 在许多实施例中,保持元件可以附接到结构以沿着天然组织表面保持结构。